middle.news
Why Is Mayne Pharma’s $408m Revenue Growth Overshadowed by a $93.8m Loss?
3:58am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Why Is Mayne Pharma’s $408m Revenue Growth Overshadowed by a $93.8m Loss?
3:58am on Saturday 30th of August, 2025 AEST
Key Points
5% revenue growth to $408.1 million in FY25
Net loss after tax improved to $93.8 million from $174.2 million
Women’s Health segment revenue up 25%, Dermatology down 12%
Acquisition scheme with Cosette Pharmaceuticals delayed by court dispute
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE